Eton Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The company is rapidly expanding its rare disease portfolio, aiming for 100 products and $500M+ peak sales by 2030. Key growth drivers include new product launches, label expansions, and a unique patient support program, with EBITDA margins expected to exceed 50% by 2028.
-
Record Q1 2026 sales and 73% product revenue growth led to raised full-year guidance above $120 million. New launches of HEMANGEOL and DESMODA, strong portfolio performance, and improved margins position the company for continued growth and profitability.
Fiscal Year 2025
-
Revenue more than doubled in 2025, driven by new product launches and strong portfolio growth. Adjusted EBITDA margin rose to 29%, with 2026 revenue expected to exceed $110M and further margin expansion. Strategic acquisitions and label expansions position the company for continued growth.
-
Record Q3 revenue rose 129% year-over-year, driven by strong growth in ALKINDI SPRINKLE, INCRELEX, and GALZIN. Adjusted gross margin was 45%, with core U.S. business exceeding 70%. Pipeline progress and disciplined expense control position the company for continued growth.
-
Record Q2 revenue grew 108% year-over-year, led by Increlex, Alkindi, and Galzin, with profitability achieved and strong cash flow. Guidance was raised, with an $80 million run rate now expected in Q3, and multiple pipeline and label expansion initiatives underway.
-
Revenue more than doubled year-over-year, driven by strong growth in Alkindi Sprinkle and the addition of Increlex. Pipeline progress, product launches, and outlicensing deals position the company for continued margin expansion and an $80 million run rate by year-end.
-
A patient-focused rare disease strategy, new product launches, and recent acquisitions are driving rapid revenue growth and margin expansion. Increlex, Galzin, and ET400 are key growth drivers, with label harmonization and pipeline launches set to unlock significant market opportunities.
Fiscal Year 2024
-
Q3 2024 saw record revenue and first positive GAAP net income, driven by strong growth in Alkindi Sprinkle and Carglumic Acid. The acquisition of Increlex and pipeline progress position the company for significant expansion in 2025.
-
Record product sales grew 40% year-over-year to $9.1 million, driven by Alkindi Sprinkle and Carglumic Acid. Positive operating cash flow was achieved, and the company expects continued growth, with major product launches and potential acquisitions ahead.